Efficacy evaluation of extravesicle, derived from Wharton's jelly's mesenchymal cells of the umbilical cord, injection in androgenetic alopecia.

Phase 2

Recruiting

• Conditions: Androgenetic alopecia.; Androgenic alopecia

• Registration Number: IRCT20140624018210N13
• Lead Sponsor: Skin and Stem Cell Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Ladies and gentlemen with androgenetic alopecia
Age 18 years and above and less than 50 years old
Hamilton score 2 to 5 in men Ludwig score 1 to 3 in women
Complete patient consent to participate in the project

Exclusion Criteria

Platelet dysfunction
Thrombocytopenia
Anticoagulant drug use
Malignancy
Chemotherapy within 5 years
Sepsis
Smoking
Pregnancy
Ulcer or infection at the site of treatment
Do not receive any topical or systemic medication in the last 3 months
Women with hyperprolactinemia
Women with hormonal dysfunction or polycystic ovarian disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alopecia severity. Timepoint: Before the start of the trial and two months after the last session. Method of measurement: Rate of change in the clinical severity of alopecia is measured by imaging with visioface. hamilton scale 1 to 6 in men.Ludwig scale 1 to 3 in women.;The amount of hair in the telogen phase. Timepoint: Before the beginning of the trial and two months after the last session. Method of measurement: The amount of hair in the telogen phase is measured by pull test.;Hair density. Timepoint: Before the beginning of the trial and two months after the last session. Method of measurement: Hair density is measured by trichoscan.;Patient satisfaction of treatment. Timepoint: Two months after the last session of treatment. Method of measurement: Patient global assessment score.;Physician satisfaction of treatment. Timepoint: Two months after the last session of treatment. Method of measurement: Physician global assessment score.